With the ink barely dry on outgoing commissioner Marty Makary’s resignation, another top regulator may be heading for the exit at the FDA. | With the ink barely dry on outgoing commissioner Marty ...
Doceree has bold ambitions to bring a new software category to pharma brand teams, one that reshapes campaign deployment in ...
With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to ...
Despite a prolonged period of policy uncertainty in the U.S.—and the ripple effects across the global life sciences and ...
Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in ...
Marty Makary, M.D., is resigning as FDA commissioner Tuesday, ending a brief but tumultuous tenure marked by mounting ...
With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...
A new survey undertaken by the Harris Poll for Johnson & Johnson has shown how standard forms of surgery and treatment for ...
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
When President Donald Trump rolled out his plan to levy a 100% tariff rate on patented pharmaceutical products and ...
Eli Lilly has made a six-year, $50 million commitment to UNICEF USA to support efforts to improve the prevention, detection ...
Generics juggernaut Sun Pharma is pulling one lot of a chemotherapy drug in the United States as the issue of particulate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results